Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
167.79
+0.15 (0.09%)
Nov 24, 2025, 10:21 AM EST - Market open

Revenue Breakdown

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202010 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2010 - 2019
Service Revenue
3.30B
Log In
Log In
Log In
Log In
Upgrade
Product Revenue
745.85M
Log In
Log In
Log In
Log In
Upgrade
Revenue (Total)
4.05B
Log In
Log In
Log In
Log In
Upgrade

Revenue Breakdown 2

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202010 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2010 - 2019
RMS Revenue
829.38M
Log In
Log In
Log In
Log In
Upgrade
DSA Revenue
2.45B
Log In
Log In
Log In
Log In
Upgrade
Manufacturing Revenue
769.33M
Log In
Log In
Log In
Log In
Upgrade
Revenue (Total)
4.05B
Log In
Log In
Log In
Log In
Upgrade

Revenue by Geography

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202010 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2010 - 2019
United States Revenue
2.24B
Log In
Log In
Log In
Log In
Upgrade
Europe Revenue
1.08B
Log In
Log In
Log In
Log In
Upgrade
Canada Revenue
482.09M
Log In
Log In
Log In
Log In
Upgrade
Asia Pacific Revenue
196.95M
Log In
Log In
Log In
Log In
Upgrade
Other Regional Revenue
52.82M
Log In
Log In
Log In
Log In
Upgrade
Revenue (Total)
4.05B
Log In
Log In
Log In
Log In
Upgrade

EBIT

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 20202010 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2010 - 2019
RMS Operating Income
114.41M
Log In
Log In
Log In
Log In
Upgrade
DSA Operating Income
442.51M
Log In
Log In
Log In
Log In
Upgrade
Manufacturing Operating Income
-71.45M
Log In
Log In
Log In
Log In
Upgrade
Corporate Operating Income
-258.12M
Log In
Log In
Log In
Log In
Upgrade
Operating Income (Total)
227.35M
Log In
Log In
Log In
Log In
Upgrade
Updated Nov 5, 2025. Data Source: Fiscal.ai.